Latest Options News

Beonic has landed a landmark AU$15.2 million contract to deploy its LiDAR passenger flow technology across seven major North African airports, marking a strategic expansion into the region ahead of a major 2030 sporting event.

Resolution Minerals Limited is set to pursue a dual-listing on the NASDAQ in Q4 2025, aiming to tap into deeper U.S. capital markets and enhance its profile among American investors. The move supports the development of its critical minerals Horse Heaven project in Idaho, aligning with U.S. national security interests.

Liontown Resources reported robust FY25 results with over 294,000 dmt of spodumene concentrate produced and commenced underground mining on schedule. The company is transitioning to 100% underground production by Q3 FY26, aiming for scalable, low-cost operations from FY27 despite a 36% drop in spodumene prices.

Syntara Limited has initiated dosing in its Phase 1a/b trial for SNT-9465, a topical drug targeting hypertrophic scars, aiming to offer a non-invasive alternative to current treatments. Results expected in early 2026 could pave the way for global development and FDA approval.

First Lithium Limited is on the cusp of securing critical mining license renewals in Mali and anticipates releasing its maiden Mineral Resource Estimate this quarter, while managing funding and exploration cost pressures.

Kalamazoo Resources retains 100% ownership of its 1.44 million ounce Ashburton Gold Project and fast-tracks a scoping study amid soaring Australian gold prices. The company aims to unlock significant value from the Mt Olympus Deposit with a targeted study completion in Q4 2025.

Clever Culture Systems advances its pharmaceutical market penetration with AstraZeneca’s full deployment and Novo Nordisk’s first order, while launching a new contact plate analysis module that doubles its APAS Independence system’s capabilities.

Bastion Mining has taken control of over 90% of Xanadu Mines shares through a takeover bid, moving swiftly to compulsory acquisition and setting the stage for the Kharmagtai project’s next phase.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Elementos Limited has delivered a robust Definitive Feasibility Study for its Oropesa Tin Project in Spain, secured a $5 million strategic investment from Metals X, and progressed exploration at its Cleveland Tin Project in Tasmania.

Urbanise.com Limited reported a 4.2% revenue increase for FY2025, driven by a landmark partnership and equity investment from National Australia Bank. The company achieved positive operating cash flow for the fourth consecutive quarter, setting the stage for its next growth phase.

Barton Gold Holdings reports robust progress in its June 2025 quarter, highlighting strong project economics, resource upgrades, and strategic acquisitions that position it for production by 2026.